You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 679 Characterization of tumor specific CD8+ T cell responses in patients with recurrent/metastatic HPV16-positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a phase 1 study

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
679 Characterization of tumor specific CD8+ T cell responses in patients with recurrent/metastatic HPV16-positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a phase 1 study

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023292018
Dec 202368014
Jan 20248909
Feb 20247007
Mar 20245803
Apr 20247006
May 20244203
Jun 20244307
Jul 202440011
Aug 20243404
Sep 20243405
Oct 20243808
Nov 20243204
Dec 202432010
Jan 20252206
Feb 20251906
Mar 20250011
Apr 2025002
May 2025108
Jun 2025006
Total9840148